Aficamten (CK-3773274)

Phase 3

Cytokinetics, Incorporated (CYTK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

CYTKPDUFA$9.1B

Phase 3

FDA PDUFA Date Aficamten (MYQORZO)

Aficamten (CK-3773274)• Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM)

Nov 14Confirmed

Source

00%

Competitive Landscape

0 competitors in Obstructive Hypertrophic Cardiomyopathy (oHCM)

View Full Landscape

Drug Information

Target Indication

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Clinical Trial

NCT05767346

Last updated: 10/20/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

CYTK

Cytokinetics, Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

tirasemtivPhase 3

Amyotrophic Lateral Sclerosis (ALS)

AficamtenPhase 3

Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Omecamtiv MecarbilPhase 3

Heart Failure With Reduced Ejection Fraction

Omecamtiv Mecarbil (OM)Phase 3

Heart Failure

Omecamtiv Mecarbil Matrix F1 FormulationPhase 2

Modified Release Oral Formulation

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts